Jax DiEugenio

The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.

TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.

The FDA approved mitomycin intravesical solution for recurrnet, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Obrixtamig combined with topotecan demonstrated favorable safety and early efficacy in relapsed/refractory SCLC.

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

Data from the phase 1 CLOVER-2 trial demonstrated the safety and activity of iopofosine I-131 in relapsed/refractory pediatric high-grade glioma.

Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.

OS Therapies submits a RMAT designation request for OST-HER2 for the treatment of patients with pediatric lung-metastatic osteosarcoma.

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

Annamycin yielded a 59.4% CBR and a median OS of 13.5 months in soft tissue sarcoma lung metastases.

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Ryan Merrell, MD, underscores the need for early glioma detection, advances in IDH-targeted therapy, and emerging immunotherapy in glioblastoma care.

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.